$256.34—
NYSE
$256.34—
AbbVie Inc. is seeking to raise at least $8 billion from an investment-grade bond offering to fund a portion of its acquisition of Apogee Therapeutics Inc.
Investors flocked to drugmaker AbbVie Inc.’s $10 billion investment-grade bond sale after signs of investor fatigue for new debt to fund artificial intelligence efforts.
AbbVie Inc. reported second quarter profit and sales that topped Wall Street’s expectations, driven by strong demand across its immunology and neuroscience franchises and further signs of a recovery in Botox.